Background: Both anagrelide and hydroxyurea effectively lower platelet counts in essential thromb... more Background: Both anagrelide and hydroxyurea effectively lower platelet counts in essential thrombocythemia (ET) and other thrombocythemic myeloproliferative neoplasms. Anagrelide has a selective inhibitory effect on megakaryopoiesis and platelet production in contrast to hydroxyurea, which is a nonspecific, myelosuppressive compound inhibiting megakaryopoiesis as well as granulopoieses and erythropiesis. Based on the superiority of hydroxyurea+aspirin over anagrelide+aspirin in ET patients in the PT1-trial, guidelines for cytoreductive therapy favor hydroxyurea as first line therapy for ET. However, the diagnosis of ET in the PT1-trial was made according to the PVSG cassification and it remains questionable if these recommendations can be applied to ET patients diagnosed according to the WHO classification. Patients and methods: In this prospective randomized single blind international multicenter phase III study efficacy and tolerability of anagrelide and hydroxyurea monotherapies ...
One hundred twenty-one anemic, transfusion-dependent patients with multiple myeloma (MM) or low-g... more One hundred twenty-one anemic, transfusion-dependent patients with multiple myeloma (MM) or low-grade non-Hodgkin's lymphoma (NHL) were randomly allocated to receive (a) recombinant human erythropoietin (rhEPO) 10,000 U/d subcutaneously 7 days a week (fixed dose group) (n = 38), or (b) rhEPO 2,000 U/d subcutaneously for 8 weeks followed by step- wise escalation of the rhEPO dose (titration group) (n = 44), or (c) no rhEPO therapy (control group) (n = 39). The total treatment period was 24 weeks. There were no differences between the three groups with regard to baseline clinical, demographic, or health status measures. The cumulative response frequency, defined as elimination of the transfusion need in combination with an increase in the hemoglobin concentration by >20 g/L, was 60% in both rhEPO treatment groups and 24% in the control group (P = .01 and .02, respectively, log rank test). For patients in the titration group the response rate on the first dose level (2,000 U/d) ...
Lymphoid cells isolated from lymph nodes, spleen and the peripheral blood were examined using the... more Lymphoid cells isolated from lymph nodes, spleen and the peripheral blood were examined using the rosette test with sheep erythrocytes (E), immunofluorescent staining of the surface immunoglobulins (SmIg) and the combined test (SmIg + E). The studies were performed on 48 patients with untreated non-Hodgkin lymphoma, 14 Hodgkin patients, 5 patients with lymphadenitis and on 132 controls. In the control group the following percentages of B-T lymphocytes were obtained: blood (n = 100); T-68 +/- 9, B-20 +/- 6, 0-11 +/- 7, BT-1 +/- 1, lymph nodes (n = 24): T-62 +/- 13, B-19 +/- 11, 0-18 +/- 8, BT-1 +/- 1, spleens (n = 8): T-45 +/- 9, B-33 +/- 9, 0-23 +/- 7, BT-1 +/- 1. In non-Hodgkin lymphoma lymph nodes a statistically significant increase of B and 'null' cells was noted in comparison to controls and to the Hodgkin lymphoma group. The characteristics of the Hodgkin nodes did not differ significantly from controls. After arranging the non-Hodgkin lymphomas according to the Kiel classification it was observed that the low-grade malignant lymphomas subtype most often an immunological 'B type' and 'mixed B/0' type was present whereas the high-grade malignant lymphoma group showed a distinct majority of 'null' cells. It was concluded that the surface markers studied allow a differentiation in most cases between the non-Hodgkin lymphomas and other disorders of the lymphoid system. They are not sufficient to distinguish the subtypes of non-Hodgkin lymphomas but do give interesting information about the more exact nature of the disorder.
Archivum immunologiae et therapiae experimentalis, 1984
Lymphocytes isolated from the blood of healthy individuals (analyzed on Parmoquant-2 apparatus) s... more Lymphocytes isolated from the blood of healthy individuals (analyzed on Parmoquant-2 apparatus) showed mean electrophoretic mobility (EM) of 1.00 +/- 0.05 um sec-1 V-1 cm and the histogram appeared to be an asymmetric curve - sum of B and T lymphocytes subpopulation. In 11 patients with chronic lymphatic leukemia (CLL) and in 4 with acute lymphatic leukemia (ALL) the histogram showed a domination of one of the population. On the other hand, in patients with chronic myeloid leukemia (CML) the histograms seem to be a sum of various populations of different mobility which was illustrated by curves of a long base and several peaks.
Blasts phenotype was determined in 61 children with the acute lymphoblastic leukemia. Non-T-cell ... more Blasts phenotype was determined in 61 children with the acute lymphoblastic leukemia. Non-T-cell acute lymphoblastic leukemia was diagnosed in 51 children. Stages of blasts differentiation were determined with the aid of monoclonal antibodies set using alkaline phosphatase-anti-alkaline phosphatase technique. Blasts in 50 patients belonged to B subpopulation confirmed by the presence of panB CD19 and CD22 antigens. Common antigen was seen in 76.5% of the examined patients with non-T-cell acute lymphoblastic leukemia. Cases of non-T-cell acute lymphoblastic leukemia were divided into 8 subgroups depending on the antigens of B-cells differentiation. An identification of pre-B subgroups of the acute lymphoblastic leukemia indicates heterogenicity of the acute lymphoblastic leukemias in childhood and enables their classification into groups corresponding to the early stages of lymphoblasts maturation.
Tardyferon was administered to 51 patients with iron deficiency anaemia. The drug was very well t... more Tardyferon was administered to 51 patients with iron deficiency anaemia. The drug was very well tolerated and even after administration to fasting patients it was tolerated well by 92% of patients. The iron absorption curve was on the average twice as high after 1 hour and increased up to 3 hours. A significant therapeutic effect with raised haemoglobin level by 10--27% was obtained after 4--6 weeks of treatment in 44 patients (86%). In the remaining cases the improvement was less pronounced.
Archivum immunologiae et therapiae experimentalis, 1978
Lymphoid cells isolated from peripheral blood and lymph nodes were examined by using the rosette ... more Lymphoid cells isolated from peripheral blood and lymph nodes were examined by using the rosette test with sheep erythrocytes (E), the immunofluorescent staining of the surface immunoglobulins (SmIg), the rosette test with mouse C 57 BL erythrocytes (Em and a combined test (SmIg + E). These studies were performed in 143 patients with various subtypes of non-Hodgkin lymphoma and in 110 controls. In the control group the following percentage of cell types was obtained: 1) blood (n = 110): T-68 +/- 12, B- 20 +/- 3, O- 11 +/- 7, BT- 1 +/- 1.4, Em+ cells--9 +/- 7, C3+ cells--21 +/- 3, 2) lymph nodes (n = 23): T- 66 +/- 10, B- 17 +/- 10, O- 15.7 +/- 9, BT- 0.8 +/- 1.7. In non-Hodgkin lymphoma lymph nodes a statistically significant increase of null and B cells- was noted in comparison to the controls (p less than 0.001). Similar changes were observed in the blood of non-Hodgkin lymphoma patients in which the leukocyte count exceeded 10(3)/microliter, whereas in the cases with low leukocyt...
Function of NK cells is regulated by a balance between inhibitory and activating signals transmit... more Function of NK cells is regulated by a balance between inhibitory and activating signals transmitted through killer immunoglobulin-like receptors (KIR). The goal of the present analysis was to evaluate the impact of donor activating KIR genotype (KIR2DS1 and KIR2DS2 loci) on outcome of unrelated donor-hematopoietic stem cell transplantation (URD-HSCT). Fourty-two URD-HSCT recipients with haematological malignancies, aged 28 (14–48) years (male/female - 26/16) were included in the analysis. The conditioning regimen was myeloablative and based on chemotherapy alone (n=33) or total body irradiation (n=9). Graft-vs-host disease (GVHD) prophylaxis consisted of cyclosporin, methotrexate, and pre-transplant anti-thymocyte globulin. Patients were grouped according to their donors’ activating KIR genotype including two loci: KIR2DS1 and KIR2DS2. The overall survival at 2.5 years with respect of the donors’ activating KIR genotype was as follows: KIR2DS1(−)DS2(−) (n=15) − 82% (+/−12%), KIR2DS...
Background: Both anagrelide and hydroxyurea effectively lower platelet counts in essential thromb... more Background: Both anagrelide and hydroxyurea effectively lower platelet counts in essential thrombocythemia (ET) and other thrombocythemic myeloproliferative neoplasms. Anagrelide has a selective inhibitory effect on megakaryopoiesis and platelet production in contrast to hydroxyurea, which is a nonspecific, myelosuppressive compound inhibiting megakaryopoiesis as well as granulopoieses and erythropiesis. Based on the superiority of hydroxyurea+aspirin over anagrelide+aspirin in ET patients in the PT1-trial, guidelines for cytoreductive therapy favor hydroxyurea as first line therapy for ET. However, the diagnosis of ET in the PT1-trial was made according to the PVSG cassification and it remains questionable if these recommendations can be applied to ET patients diagnosed according to the WHO classification. Patients and methods: In this prospective randomized single blind international multicenter phase III study efficacy and tolerability of anagrelide and hydroxyurea monotherapies ...
One hundred twenty-one anemic, transfusion-dependent patients with multiple myeloma (MM) or low-g... more One hundred twenty-one anemic, transfusion-dependent patients with multiple myeloma (MM) or low-grade non-Hodgkin's lymphoma (NHL) were randomly allocated to receive (a) recombinant human erythropoietin (rhEPO) 10,000 U/d subcutaneously 7 days a week (fixed dose group) (n = 38), or (b) rhEPO 2,000 U/d subcutaneously for 8 weeks followed by step- wise escalation of the rhEPO dose (titration group) (n = 44), or (c) no rhEPO therapy (control group) (n = 39). The total treatment period was 24 weeks. There were no differences between the three groups with regard to baseline clinical, demographic, or health status measures. The cumulative response frequency, defined as elimination of the transfusion need in combination with an increase in the hemoglobin concentration by >20 g/L, was 60% in both rhEPO treatment groups and 24% in the control group (P = .01 and .02, respectively, log rank test). For patients in the titration group the response rate on the first dose level (2,000 U/d) ...
Lymphoid cells isolated from lymph nodes, spleen and the peripheral blood were examined using the... more Lymphoid cells isolated from lymph nodes, spleen and the peripheral blood were examined using the rosette test with sheep erythrocytes (E), immunofluorescent staining of the surface immunoglobulins (SmIg) and the combined test (SmIg + E). The studies were performed on 48 patients with untreated non-Hodgkin lymphoma, 14 Hodgkin patients, 5 patients with lymphadenitis and on 132 controls. In the control group the following percentages of B-T lymphocytes were obtained: blood (n = 100); T-68 +/- 9, B-20 +/- 6, 0-11 +/- 7, BT-1 +/- 1, lymph nodes (n = 24): T-62 +/- 13, B-19 +/- 11, 0-18 +/- 8, BT-1 +/- 1, spleens (n = 8): T-45 +/- 9, B-33 +/- 9, 0-23 +/- 7, BT-1 +/- 1. In non-Hodgkin lymphoma lymph nodes a statistically significant increase of B and 'null' cells was noted in comparison to controls and to the Hodgkin lymphoma group. The characteristics of the Hodgkin nodes did not differ significantly from controls. After arranging the non-Hodgkin lymphomas according to the Kiel classification it was observed that the low-grade malignant lymphomas subtype most often an immunological 'B type' and 'mixed B/0' type was present whereas the high-grade malignant lymphoma group showed a distinct majority of 'null' cells. It was concluded that the surface markers studied allow a differentiation in most cases between the non-Hodgkin lymphomas and other disorders of the lymphoid system. They are not sufficient to distinguish the subtypes of non-Hodgkin lymphomas but do give interesting information about the more exact nature of the disorder.
Archivum immunologiae et therapiae experimentalis, 1984
Lymphocytes isolated from the blood of healthy individuals (analyzed on Parmoquant-2 apparatus) s... more Lymphocytes isolated from the blood of healthy individuals (analyzed on Parmoquant-2 apparatus) showed mean electrophoretic mobility (EM) of 1.00 +/- 0.05 um sec-1 V-1 cm and the histogram appeared to be an asymmetric curve - sum of B and T lymphocytes subpopulation. In 11 patients with chronic lymphatic leukemia (CLL) and in 4 with acute lymphatic leukemia (ALL) the histogram showed a domination of one of the population. On the other hand, in patients with chronic myeloid leukemia (CML) the histograms seem to be a sum of various populations of different mobility which was illustrated by curves of a long base and several peaks.
Blasts phenotype was determined in 61 children with the acute lymphoblastic leukemia. Non-T-cell ... more Blasts phenotype was determined in 61 children with the acute lymphoblastic leukemia. Non-T-cell acute lymphoblastic leukemia was diagnosed in 51 children. Stages of blasts differentiation were determined with the aid of monoclonal antibodies set using alkaline phosphatase-anti-alkaline phosphatase technique. Blasts in 50 patients belonged to B subpopulation confirmed by the presence of panB CD19 and CD22 antigens. Common antigen was seen in 76.5% of the examined patients with non-T-cell acute lymphoblastic leukemia. Cases of non-T-cell acute lymphoblastic leukemia were divided into 8 subgroups depending on the antigens of B-cells differentiation. An identification of pre-B subgroups of the acute lymphoblastic leukemia indicates heterogenicity of the acute lymphoblastic leukemias in childhood and enables their classification into groups corresponding to the early stages of lymphoblasts maturation.
Tardyferon was administered to 51 patients with iron deficiency anaemia. The drug was very well t... more Tardyferon was administered to 51 patients with iron deficiency anaemia. The drug was very well tolerated and even after administration to fasting patients it was tolerated well by 92% of patients. The iron absorption curve was on the average twice as high after 1 hour and increased up to 3 hours. A significant therapeutic effect with raised haemoglobin level by 10--27% was obtained after 4--6 weeks of treatment in 44 patients (86%). In the remaining cases the improvement was less pronounced.
Archivum immunologiae et therapiae experimentalis, 1978
Lymphoid cells isolated from peripheral blood and lymph nodes were examined by using the rosette ... more Lymphoid cells isolated from peripheral blood and lymph nodes were examined by using the rosette test with sheep erythrocytes (E), the immunofluorescent staining of the surface immunoglobulins (SmIg), the rosette test with mouse C 57 BL erythrocytes (Em and a combined test (SmIg + E). These studies were performed in 143 patients with various subtypes of non-Hodgkin lymphoma and in 110 controls. In the control group the following percentage of cell types was obtained: 1) blood (n = 110): T-68 +/- 12, B- 20 +/- 3, O- 11 +/- 7, BT- 1 +/- 1.4, Em+ cells--9 +/- 7, C3+ cells--21 +/- 3, 2) lymph nodes (n = 23): T- 66 +/- 10, B- 17 +/- 10, O- 15.7 +/- 9, BT- 0.8 +/- 1.7. In non-Hodgkin lymphoma lymph nodes a statistically significant increase of null and B cells- was noted in comparison to the controls (p less than 0.001). Similar changes were observed in the blood of non-Hodgkin lymphoma patients in which the leukocyte count exceeded 10(3)/microliter, whereas in the cases with low leukocyt...
Function of NK cells is regulated by a balance between inhibitory and activating signals transmit... more Function of NK cells is regulated by a balance between inhibitory and activating signals transmitted through killer immunoglobulin-like receptors (KIR). The goal of the present analysis was to evaluate the impact of donor activating KIR genotype (KIR2DS1 and KIR2DS2 loci) on outcome of unrelated donor-hematopoietic stem cell transplantation (URD-HSCT). Fourty-two URD-HSCT recipients with haematological malignancies, aged 28 (14–48) years (male/female - 26/16) were included in the analysis. The conditioning regimen was myeloablative and based on chemotherapy alone (n=33) or total body irradiation (n=9). Graft-vs-host disease (GVHD) prophylaxis consisted of cyclosporin, methotrexate, and pre-transplant anti-thymocyte globulin. Patients were grouped according to their donors’ activating KIR genotype including two loci: KIR2DS1 and KIR2DS2. The overall survival at 2.5 years with respect of the donors’ activating KIR genotype was as follows: KIR2DS1(−)DS2(−) (n=15) − 82% (+/−12%), KIR2DS...
Uploads
Papers by Jerzy Holowiecki